Primaa

Primaa is a French MedTech company founded in 2018, focused on AI-powered software platforms for pathologists. The company aims to enhance cancer diagnosis through automated image analysis and deep learning. Its flagship product, Cleo, assists in identifying breast cancer biomarkers and is CE-IVD marked for use in Europe. Primaa's solutions improve workflow efficiency, diagnostic confidence, and personalized patient care.

Headquartered in Paris, Primaa originated from the vision of pathologist Marie to automate repetitive tasks in pathology. The company has achieved significant milestones, including the development of its first prototype in 2019 and the publication of clinical results confirming Cleo's safety and efficacy in 2021. Primaa collaborates with leading organizations in digital pathology, including a partnership with Gestalt Diagnostics to integrate its AI into the PathFlow platform for skin cancer diagnosis. The company emphasizes validated tools designed by pathologists to enhance case reviews and patient outcomes.